What Most Influences IVF Success?
Key Takeaways
IVF results depend on several linked factors. Age when the eggs are used matters, and so do the ovarian response, the embryo and sperm, the uterus, and how well the plan fits the diagnosis. A clinic's success rate describes a group of patients, not your own chance. Before an extra test or treatment, ask who it was studied in, what outcome was counted, and how strong the evidence is.
Key evidence: ACOG/ASRM: Female age-related fertility decline (Committee Opinion 589) SART: Patient guide to ART success rates ESHRE: Good practice recommendations on add-ons in reproductive medicine
People often look for one number, or one extra step, that will decide an IVF cycle.
There is no single secret. Several factors work together, and none of them should be read on its own.
Age and ovarian reserve
Age at the time the eggs are used is a major factor in IVF results. Fertility declines gradually from about age 32 and faster after 37 (ACOG/ASRM, 2014). Age is also linked to the number of eggs that may be collected and to the chance of a chromosome problem in the embryo: the share of chromosomally normal embryos falls as maternal age rises (Gao et al., 2023).
Ovarian reserve tests help estimate how the ovaries may respond to stimulation. The two usual tests are a blood test for anti-Müllerian hormone (AMH) and the antral follicle count. That count is the number of small follicles seen on ultrasound. These tests do not measure egg quality. They should not be used on their own to predict pregnancy or live birth. Live birth means a baby born alive, not only a positive pregnancy test. The American Society for Reproductive Medicine (ASRM) advises reading them alongside age, diagnosis, past treatment, and past response (ASRM, ovarian reserve guidance).
Embryo and sperm biology
Embryo grade describes how an embryo looks. It does not show whether the chromosomes are normal. Better grades go with higher rates of normal chromosomes on average, but an embryo with a good grade can still have a chromosome abnormality (Gao et al., 2023; Baltaci et al., 2006).
Grading gives the laboratory useful information about morphology, meaning the embryo’s appearance. That includes the developmental stage, the inner cell mass (the cells that can become the fetus), and the trophectoderm (the cells that can become the placenta) (ASRM, embryo grading scales). It remains a visual assessment, and an embryo that looks less favourable may still implant.
A semen analysis looks at sperm concentration, motility (movement), and shape. These results help the team judge how much a male factor contributes. Sperm DNA integrity may be relevant in selected situations, but the AUA/ASRM guideline advises against routine DNA fragmentation analysis in the initial evaluation of a couple (AUA/ASRM guideline, part I). What any result means depends on the couple’s history and the clinical question.
Matching treatment to the case
The plan is adjusted to the medical picture and to the response seen during the cycle. The discussion may include:
- Stimulation: Choosing and adjusting gonadotropins, the injectable hormones that stimulate the ovaries. The aim is to reduce the risk of a very low response or of ovarian hyperstimulation syndrome (OHSS) (ESHRE ovarian stimulation guideline). In OHSS, the ovaries swell after an exaggerated response. See ovarian stimulation in IVF.
- Transfer strategy: Choosing between a fresh transfer and a frozen-embryo transfer. The team considers progesterone levels, the uterine lining, the embryos available, the diagnosis, and the circumstances of the cycle. No single measurement picks the right option for everyone. How many embryos to transfer is a separate decision, and ASRM publishes guidance on those limits.
- Uterine assessment: Looking for a finding that could change transfer planning. A polyp or fibroid is not automatically a reason for treatment. Routine polyp removal in women who struggle to conceive is not supported by the evidence (Vitale et al., 2021), and a fibroid is mainly considered for removal when it distorts the uterine cavity (ASRM, 2017). Location, size, symptoms, and effect on the cavity matter.
The same caution applies to IVF add-ons, the extra tests and treatments offered on top of standard IVF. The European Society of Human Reproduction and Embryology (ESHRE) has published good-practice recommendations on add-ons. Before an add-on is considered, patients should be told what is known about its safety and its chance of improving live birth. Evidence varies from one add-on to another. Being commercially available does not make an add-on a routine part of treatment (ESHRE add-on recommendations). Comfort from acupuncture or herbal remedies is not the same as evidence of more live births. If you are planning another cycle, ways to improve IVF success sets out the order of decisions.
How to read clinic success rates
A clinic average is a group figure, not a personal forecast.
Published figures are still useful for comparison if you ask the right questions about them (SART). Overall averages depend heavily on patient mix: age, diagnosis, and case complexity.
Compare rates by age group, treatment type, and how the outcome is defined. A rate per embryo transfer is not the same as a rate per started cycle. Neither is the same as a cumulative live-birth rate, which counts live births from all the transfers that follow one egg collection. Our IVF success-rate methodology explains the context used on this site.
Dr. Aksoy’s Approach
Dr. Aksoy’s approach: After a previous cycle, the treatment history is usually what changes my plan. It shows where the process actually stalled: ovarian response, egg maturity, fertilisation, embryo development, or implantation. Before a first cycle, female age and ovarian reserve still decide a great deal. One failed cycle does not, by itself, justify extra tests or treatments. First identify a specific problem. Then ask whether the proposed extra has evidence of benefit — ideally for live birth — in a comparable patient group. Many add-ons raise cost and complexity without a shown benefit. The useful question is not “What can we add?” It is “What obstacle have we actually found, and could this treatment reasonably correct it?”
Frequently Asked Questions for Dr. Aksoy
Does IVF work if the woman is infertile?
Yes. Helping couples who have difficulty conceiving naturally is what IVF is for. What matters is why the woman has not conceived.
In a woman whose tubes are blocked, for example, IVF can be quite effective, because we fertilise the egg in the laboratory and remove the need for the tubes. We can also get good results in women with ovulation disorders. The situation is different if ovarian reserve is very low or the woman is older. IVF cannot turn back the clock: it does not restore the number of eggs or their chromosomal quality. Some uterine problems may also need to be assessed before transfer.
I tell my patients that an infertility diagnosis, on its own, does not mean IVF will fail. The real question is what is blocking pregnancy and how far IVF can get around that obstacle. That is why I assess the chance of success from the woman’s age, her ovarian reserve, the state of the uterus, and her partner’s sperm results, not from the infertility diagnosis alone.
How do you avoid OHSS during IVF?
OHSS (ovarian hyperstimulation syndrome) is a condition we may see during IVF, especially in women whose ovaries over-respond to the medicines. Today, with the right treatment plan, we can reduce that risk substantially.
The most important point for me is to identify the woman at risk before treatment starts. I am more careful in women with polycystic ovary syndrome, a high AMH level, or a large number of follicles on ultrasound. We do not give every patient the same dose. We set the starting dose according to ovarian reserve and the expected response, and we monitor follicle growth with ultrasound scans.
In high-risk patients we usually prefer an antagonist protocol. Using a GnRH agonist trigger before egg collection, instead of the classic hCG trigger injection, can markedly reduce the risk of OHSS. When needed, we freeze all the embryos and leave the transfer for a later cycle. This also lowers the risk of a pregnancy making OHSS worse. In some patients we can use additional protective medicines as well.
Of course, it is not possible to eliminate the risk completely. My approach is not to collect as many eggs as possible, but to obtain enough mature eggs while keeping the patient safe.
Does a high-grade embryo guarantee pregnancy?
No, unfortunately it does not. Of course, a very good grade from the embryology laboratory, such as 4AA or 5AA, is welcome news. But I make a point of telling my patients that these grades describe how the embryo looks under the microscope. They do not show that it is chromosomally healthy.
A 4AA embryo can have a chromosomal abnormality, for example, while a lower-graded embryo such as 3BB or 5BC can still lead to a healthy pregnancy. That said, appearance is not irrelevant. In general, good-quality blastocysts are more likely to implant and lead to a live birth. But that only tells us about probability.
The woman’s age, how many days the embryo took to develop, its chromosomal make-up, and uterine factors also affect the result. Even an embryo with a normal chromosome number after PGT-A (a genetic test of chromosome number on a few cells taken from the embryo) does not guarantee pregnancy.
That is why I do not think it is right to give a definite success percentage from embryo grade alone. For me, the grade helps us decide which embryo to transfer first; it is not a guarantee of pregnancy.
Conclusion
IVF planning is clearer when you separate what a test can measure from what it cannot, and when you compare outcomes using the same definitions.
| What you are looking at | What it helps estimate | What it does not tell you |
|---|---|---|
| Age when the eggs are used | How many eggs are likely, and the chromosome risk in the embryo | The result of one cycle |
| AMH and antral follicle count | How the ovaries may respond, and how many eggs might be collected | Egg quality, pregnancy, or live birth |
| Embryo grade | Appearance and stage | Whether the chromosomes are normal |
| Clinic headline rate | A group figure | Your own chance, unless the age mix, treatment type, and outcome match your situation |
The useful questions are usually practical: What is the main clinical problem? Which finding would change the plan? What outcome does the quoted rate describe? And what evidence supports any proposed add-on?
Sources
- Society for Assisted Reproductive Technology. Success rates.
- European Society of Human Reproduction and Embryology. Ovarian stimulation for IVF/ICSI guideline.
- American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114:1151-1157.
- American Society for Reproductive Medicine. Grading scales for embryo morphology.
- European Society of Human Reproduction and Embryology. Good practice recommendations on add-ons in reproductive medicine.
- American Society for Reproductive Medicine. Guidance on the limits to the number of embryos to transfer: a committee opinion (2021).
- American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine. Female age-related fertility decline: Committee Opinion No. 589. Fertil Steril. 2014;101:633-634.
- Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. Fertil Steril. 2021;115:54-61.
- Gao J, Wei N, Zhu X, et al. The correlation between morphological parameters and the incidence of de novo chromosomal abnormalities in 3238 biopsied blastocysts. J Assist Reprod Genet. 2023;40:1089-1098.
- Baltaci V, Satiroglu H, Kabukçu C, et al. Relationship between embryo quality and aneuploidies. Reprod Biomed Online. 2006;12:77-82.
- Practice Committee of the American Society for Reproductive Medicine. Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline. Fertil Steril. 2017;108:416-425.
- Vitale SG, Haimovich S, Laganà AS, et al. Endometrial polyps. An evidence-based diagnosis and management guide. Eur J Obstet Gynecol Reprod Biol. 2021;260:70-77.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.